Validation of the Chinese version of the Canadian Haemophilia Outcomes‐Kids' Life Assessment Tool (the <scp>CHO</scp>‐<scp>KLAT</scp>)

Wu, Runhui; Zhang, J.; Sun, Jing; Zhou, Min; Wu, Jim Zhen; Li, N.; Li, X.; Luke, Koon Hung; Poon, Man‐Chiu; Blanchette, Victor S.; Young, Nancy L.

doi:10.1111/hae.12489

Cited by 11 publications

(23 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These analyses enabled us to confirm or adjust the CHO-KLAT scores previously reported by this team. 10 All analyses were performed using STATA version 14.1 for…”

Section: Discussionmentioning

confidence: 99%

“…This time period has been previously used by the investigator team as part of the definition of prophylaxis in studies in China. 10 Basic clinical data were gathered retrospectively, including: the frequency of prophylaxis, factor consumption and bleeding rates.…”

Section: Methodsmentioning

confidence: 99%

“…The CHO-KLAT had been previously adapted 11 and validated 10 for boys with haemophilia living in China. The Chinese version of the CHO-KLAT has an additional unique Socio-Economic Context (SEC) module, which is comprised of 9 items.…”

Section: Methodsmentioning

confidence: 99%

“…8,9 The current version of the CHO-KLAT (version 2.0) contains 35 items and has two formats: one for child self-report, and the other for parent proxy- 10 and was the only haemophilia-specific HR-QoL measure to meet this requirement at the time of this study. Preliminary data from China suggest that CHO-KLAT scores were higher (better) in boys who received prophylaxis 3 times/week for >24 weeks, as compared to boys who were treated with on-demand therapy or who received twice weekly FVIII infusions.…”

Section: Introductionmentioning

confidence: 99%

“…Preliminary data from China suggest that CHO-KLAT scores were higher (better) in boys who received prophylaxis 3 times/week for >24 weeks, as compared to boys who were treated with on-demand therapy or who received twice weekly FVIII infusions. 10 The objective of this cross-sectional study was to determine the HR-QoL of boys (< 18 years of age) with haemophilia in China, to act as a reference point for future clinical trials of prophylaxis in boys with moderate/severe haemophilia in China.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Describing the quality of life of boys with haemophilia in China: Results of a multicentre study using the CHO‐KLAT

Tang

et al. 2017

Haemophilia

Self Cite

View full text Add to dashboard Cite

Introduction The treatment of haemophilia varies across countries and across regions within some countries. Similar variation has been observed in health‐related quality of life (HR‐QoL). Relatively little is known about the HR‐QoL of boys with haemophilia in China. Aim The aim of this study was to describe the HR‐QoL of boys with haemophilia in China using the Canadian Haemophilia Outcomes‐Kids Life Assessment Tool (CHO‐KLAT). Methods Boys (4‐18 years of age) with haemophilia and their parents were enroled in a cross‐sectional study. All parents/guardians of study subjects were requested to complete a CHO‐KLAT questionnaire during a clinic visit, and report on several other clinical and socioeconomic factors in the past year. Boys who were > 7 years also completed the CHO‐KLAT. Results A total of 269 parents of boys with haemophilia, from 13 hospitals in 12 provinces, were enroled during 2014. The boys ranged from 4.0 to 17.9 years of age; 91% had haemophilia A, most had moderate (52%) or severe (36%) disease, and most were receiving sub‐optimal on‐demand therapy or low‐dose prophylactic therapy. Child self‐report CHO‐KLAT scores were available for 171 boys ≥7 years of age and ranged from 24.2 to 85.3 with a mean of 57.6 (n = 171). Parent proxy‐reported CHO‐KLAT scores ranged from 25.0 to 88.7 with a mean of 55.1 (n = 269). Conclusion HR‐QoL scores in boys with haemophilia in China were substantially lower than reported from Canadian and European boys with haemophilia. Longer term prospective studies are required to examine the factors impacting the HR‐QoL for boys with haemophilia in China.

show abstract

“…These analyses enabled us to confirm or adjust the CHO-KLAT scores previously reported by this team. 10 All analyses were performed using STATA version 14.1 for…”

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Describing the quality of life of boys with haemophilia in China: Results of a multicentre study using the CHO‐KLAT

Tang

et al. 2017

Haemophilia

Self Cite

View full text Add to dashboard Cite

show abstract

Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries

Usuba

Price

Blanchette

et al. 2019

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Background Prophylaxis reduces the frequency of bleeds in boys with severe hemophilia and is the standard care for their management in resource‐abundant countries. The effect of prophylaxis on Health‐Related Quality of Life (HRQoL) has not been established, because the sample sizes of most studies are too small to explore the relationship of multiple factors that influence HRQoL. Methods The aim of this study was to assess the impact of hemophilia severity and treatment regimen on HRQoL and to establish the minimum important difference (MID) using the international level of score distributions. HRQoL data were pooled from 7 studies across 9 countries. HRQoL was measured using the Canadian Hemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT). A mixed‐effect linear regression analysis was employed to assess the impact of prophylaxis on the CHO‐KLAT score. Results Data from 401 boys with hemophilia were analyzed (57.6% severe hemophilia and 57.6% receiving prophylaxis). The model revealed that receiving prophylaxis was significantly associated with higher HRQoL (regression coefficient 8.5, 95% confidence interval [CI] 3.9‐13.1). Boys with severe hemophilia had a significantly lower HRQoL as compared to boys with moderate and mild hemophilia whose CHO‐KLAT scores were 7.0 and 6.6 points higher, respectively. There was a significant interaction between treatment and disease severity (P = 0.023), indicating prophylaxis has the most significant impact in boys with severe hemophilia. Based on these pooled data, the MID of the CHO‐KLAT was established at 6.5. Conclusions This study confirms the positive effect of prophylaxis on HRQoL in boys with hemophilia in a real‐world setting and provides initial benchmarks for interpreting HRQoL scores based on use of the CHO‐KLAT instrument.

show abstract

The benefit of low dose prophylaxis in the treatment of hemophilia: a focus on China

Luke

2017

Expert Review of Hematology

View full text Add to dashboard Cite

Currently full dose prophylaxis is the standard of care in the treatment of hemophilia (World Federation of Hemophilia). However, the high costs prevent the use of standard or intermediate dose prophylaxis in China and other developing countries. Low dose prophylaxis would be a viable alternative treatment. At present global research data on the use of low dose prophylaxis is limited. Areas covered: Since 2007, China has been developing low dose prophylaxis as a high priority (90 % of moderate and severe hemophilia boys suffer joint disease by age 6 - 9). 11 studies were successfully conducted and published results showing evidence of the benefits of low dose prophylaxis to reduce joint bleeding. This new knowledge has been implemented into clinical practice in China. However the long-term outcome of arthropathy remains unclear and obstacles in execution exist. Expert commentary: In 2016, the first phenotype-based individualized prophylaxis study using four escalating low dose regimens on severe Chinese hemophilia A boys (China Individualized Prophylaxis Study (CHIP China)) launched. Using the previously published and imminent CHIP data, the goal for China is to establish an effective escalating low dose prophylaxis protocol for use in China as a standard of care.

show abstract

Validation of the Chinese version of the Canadian Haemophilia Outcomes‐Kids' Life Assessment Tool (the CHO‐KLAT)

Cited by 11 publications

References 13 publications

Describing the quality of life of boys with haemophilia in China: Results of a multicentre study using the CHO‐KLAT

Describing the quality of life of boys with haemophilia in China: Results of a multicentre study using the CHO‐KLAT

Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries

The benefit of low dose prophylaxis in the treatment of hemophilia: a focus on China

Contact Info

Product

Resources

About